問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 1,704

    Total Beds

  • 806

    Total Doctors

  • ctc@ms.kmuh.org.tw
  • Yu-Sam Lin
  • 886-7-3121101#6643
  • 807Kaohsiung CityKaohsiung SanminNo.100, Tzyou 1st Rd., Sanmin Dist.,Sanmin,Kaohsiung City 807

Recruiting Trial

551Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1268Cases

2026-05-31 - 2030-06-30

Phase III

Not yet recruiting
A Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial evaluating the efficacy, safety, and tolerability of cenerimod in combination with background therapy in adult patients with systemic lupus erythematosus and active lupus nephritis.

  • Condition/Disease

    Nephritis and nephropathy not specified as acute or chronic, classified elsewhere | Systemic lupus erythematosus

  • Test Drug

    Cenerimod

Participate Sites
9Sites

Not yet recruiting9Sites

2019-11-01 - 2024-05-13

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2019-11-01 - 2026-12-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2019-11-30 - 2026-09-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2019-12-01 - 2022-12-31

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2019-12-01 - 2025-06-16

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2020-01-01 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2020-01-11 - 2027-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2020-01-01 - 2026-06-30

Phase II/III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2020-01-09 - 2026-02-28

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5 127
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB